

1 **Probiotic supplements reduce antipsychotic-induced metabolic**
2 **disturbances in drug-naïve first-episode schizophrenia**

3 Dongyu Kang, M.D.^{a#}, Fengyu Zhang, PhD. MS^{b,c#}, Ye Yang, M.D.^a, Chenchen Liu,
4 M.D.^a, Jingmei Xiao, M.D.^a, Yujun Long, M.D.^a, Jing Huang, M.D. PhD.^a, Xingjie
5 Peng, M.D.^a, Weiyan Wang, M.D.^a, Xiaoyi Wang, M.D.^a, John M. Davis, M.D.^d,
6 Jingping Zhao M.D. PhD.^a, Renrong Wu M.D. PhD.^{a,e*}

7 **Affiliation/address:**

- 8 a. National Clinical Research Center for Metabolic Diseases, and Department of
9 Psychiatry, the Second Xiangya Hospital of Central South University, Changsha
10 410011, Hunan, China.
11 b. Beijing Huilongguan Hospital and Peking University Huilongguan Clinical
12 Medical School, Beijing, China
13 c. Global Clinical and Translational Research Institute, Bethesda, MD, USA
14 d. Psychiatric Institute, University of Illinois, Chicago, IL, USA
15 e. Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
16 Shanghai 200031, China
17 # Authors contributed equally to this work.

18 ***Corresponding author and E-mail address:**

19 Renrong Wu, MD PhD
20 Mental Health Institute of the Second Xiangya Hospital
21 Central South University
22 Changsha, Hunan
23 China
24 E-mail: wurenrong@csu.edu.cn
25 Tel: +86 15874179855 ; Fax: +86 73185295214

26
27 Word count 4108, 4 Table, 2 Figure.

28
29 Keywords: schizophrenia, probiotic, antipsychotic, metabolic dysfunction
30
31

32 **ABSTRACT**

33 Probiotic supplements have demonstrated efficacy in improving metabolic
34 abnormalities and may prevent antipsychotic-induced metabolic disturbance and
35 weight gain. A few studies in rodents have found that antipsychotic-induced
36 metabolic dysfunctions are associated with the altered composition of gut microbiota.
37 Here, we conducted a randomized-controlled clinical trial to determine the
38 effectiveness and safety of probiotic supplements on antipsychotic-induced
39 metabolic disturbance and weight gain. Patients with drug-naïve first-episode
40 schizophrenia were randomized to receive either olanzapine plus probiotics or
41 olanzapine monotherapy and scheduled to evaluate with follow-ups for clinical and
42 metabolic profiles. After a treatment of 12 weeks with addition of probiotics, the
43 increase of mean fasting insulin was significantly lower than olanzapine
44 monotherapy. Insulin resistance increased considerably in the olanzapine plus
45 probiotics, but also significantly lower than olanzapine monotherapy. We noted a
46 difference in the increase in body mass index and body weight between treatments at
47 a nominal level of significance, but it became non-significant after adjusting for
48 appetite increase. Probiotics concurrently used with olanzapine is effective and safe
49 in attenuating antipsychotic-induced elevation of fasting insulin and insulin
50 resistance, but not the weight gain in drug-naïve first-episode schizophrenia. Further
51 study is warranted to assess the longer-term maintenance of efficacy and safety.

52

53 **1. Introduction**

54 The second-generation antipsychotics (SGAs) are widely used as first-line
55 medications to treat and manage patients with schizophrenia. However,
56 antipsychotics-induced weight gain and metabolic dysregulations such as
57 hyperglycemia and hyperlipidemia are of significant concern (Newcomer, 2007).
58 These side effects not only affect the patients' compliance with antipsychotic
59 medications but also cause substantial medical morbidities such as diabetes,
60 cardiovascular disease, stroke, and premature death (De Hert et al., 2011; Foley and
61 Morley, 2011). Antipsychotic drugs have sharply increased in the prescription of
62 children and adolescents and are shown to cause significant weight gain and risk for
63 type 2 diabetes (Maayan and Correll, 2011). Of the SGAs, olanzapine is one of the
64 commonly used and has better efficacy than other drugs in patients with chronic
65 schizophrenia (Lieberman et al., 2005). In a large cohort study about the SGAs
66 Treatment Indications, Effectiveness, and Tolerability in Youth Study (SATIETY),
67 the proportion of individuals who gain more than 7% of weight over the baseline
68 during the first three months is 84% in olanzapine and 64% in risperidone (Correll et
69 al., 2009).

70 The exact mechanism of antipsychotic-induced weight gain and metabolic disturbance
71 has not been elucidated (Nasrallah, 2008; Newcomer, 2005). Animal studies have
72 indicated that the initial weight gain in individuals using olanzapine is primarily
73 driven by the increases in appetite and food intakes (Davoodi et al., 2009), which is
74 likely caused by the antagonism of histamine H₁ receptors and 5-HT_{2C} in the presence
75 of dopamine D₂ receptors (Kirk et al., 2009); whereas others show that risperidone
76 induced weight gain is partly attributable to the alteration of gut microbiome and

77 suppression of energy expenditure (Bahra et al., 2015). In addition, antipsychotics can
78 inhibit the insulin-signaling pathway in the target cells such as muscle cells,
79 hepatocytes and adipocytes from using glucose, and, therefore, cause insulin
80 resistance, which is independent of weight gain and food intake that has been
81 indicated in both patients and healthy controls using antipsychotics (Hahn et al., 2013;
82 van Winkel et al., 2008). Further, the induced obesity can result in high levels of free
83 fatty acids (FFA) and inflammation, which can cause insulin resistance, and
84 antipsychotics can cause direct damage to β -cells, leading to dysfunction and
85 apoptosis of β -cells that increase insulin resistance (Chen et al., 2017).

86 Antipsychotic-induced metabolic dysfunctions are likely linked to the altered
87 composition of the gut microbiota caused by using antipsychotics. The gut microbiota
88 contains about 500 to 1000 different microorganisms, and the *firmicutes*,
89 *bacteroidetes*, *actinobacteria*, and *proteobacteria* are four dominant bacterial phyla in
90 the human gut (Khanna and Tosh, 2014). In germ-free mice, the gut microbiota has
91 been demonstrated as an important environmental factor that regulates energy harvest
92 and storage in the host and plays a critical role in the healthy weight gain and fat
93 composition (Bäckhed et al., 2004; Backhed et al., 2007). Compared with
94 conventionally raised mice, germ-free mice tend to have less total fat and are resistant
95 to diet-induced obesity, which is likely through two complementary, but independent
96 mechanisms of 1) elevated levels of the fasting-induced adipose factor (Fiaf), which
97 induces a key regulator (Pgc-1a) of energy metabolism and 2) increased adenosine
98 monophosphate activated protein kinase (AMPK) activity that increases the
99 metabolism of fatty acids (Backhed et al., 2007). In a double-blind, randomized,
100 placebo-controlled parallel-group clinical trial, glycemic conditions are improved by
101 probiotics and particularly synbiotic supplements in pre-diabetic individuals

102 (Kassaian et al., 2018). In addition, in rats chronically treated with olanzapine, altered
103 fecal microbiota profiles were observed, and they might be associated with metabolic
104 effects induced by olanzapine (Davey et al., 2012). Supplementation of vitamin D
105 plus probiotics also showed clinical and metabolic improvements compared with the
106 placebo in patients with schizophrenia (Ghaderi et al., 2019) who had been treated
107 with chlorpromazine and anticholinergic agents but not concurrently treated with
108 probiotics in the past six months.

109 The investigations of agents such as antibiotics and probiotics in olanzapine-induced
110 metabolic dysfunctions (Davey et al., 2013), metabolic diseases, and obesity have
111 been encouraging in animal models (Cani et al., 2008; Murphy et al., 2013).
112 Although the number of existing studies about antipsychotics on the gut microbiota
113 is limited, a few studies in rodents have found that olanzapine- and
114 risperidone-induced weight gain and metabolic dysfunction were associated with the
115 changes in the gut microbiota (Bahra et al., 2015; Bretler et al., 2019). However, a
116 minimal number of studies have been conducted in humans (Kang et al., 2019), in
117 particular on antipsychotics-induced metabolic disturbances. A longitudinal study of
118 five male adolescents with psychiatric disorders treated with risperidone showed that
119 a gradual increase in the ratio of *Firmicutes* to *Bacteroidetes* was associated with an
120 increase in body mass index (BMI) compared with antipsychotic-naïve psychiatric
121 controls, and the gut microbiome of the participants was enriched with genes for
122 short-chain fatty acids (SCFA) and serotonin metabolism (Bahr et al., 2015).
123 However, no other outcome measures were evaluated. In this study, we assessed the
124 efficacy of probiotics supplements in preventing olanzapine-induced metabolic
125 disturbance and weight gain in drug-naïve first-episode patients with schizophrenia.

126 **2. Material and methods**

127 *2.1 Trial design*

128 This study was a randomized-controlled clinical trial designed to evaluate the
129 efficacy of probiotics for reducing olanzapine-induced metabolic disturbance and
130 weight gain. Participants were randomly assigned (without any restriction or
131 stratification) through a computer-generated random number to the treatment of
132 either olanzapine plus probiotics (olanzapine +) or olanzapine monotherapy in
133 blocks of 4 to ensure approximately equal numbers of participants within the two
134 treatment groups. The treatment assignment (randomization) was determined after
135 the completion of all assessments and acceptance into the study.

136 The authors assert that all procedures contributing to this work comply with the
137 ethical standards of the relevant national and institutional committees on human
138 experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All
139 procedures involving human patients were approved by the ethics committee of the
140 Second Xiangya Hospital of Central South University (2017-027). Written informed
141 consent was obtained from all patients.

142 *2.2 Participants*

143 All participants were recruited (November 30, 2017 to February 01, 2019) by
144 clinical investigators from the Department of Psychiatry of the Second Xiangya
145 Hospital at Central South University, China. Patients were aged 18 to 50 years, the
146 first psychotic episode of schizophrenia and met diagnostic criteria of the Diagnostic
147 and Statistical Manual of Mental Disorders Fifth Edition (DSM-V). All patients were
148 ensured not having used any antipsychotics or recreational drugs at least three

149 months before enrollment and without abnormal in physical examinations,
150 laboratories, and electrocardiogram (ECG) tests.

151 Exclusions: 1) female patients who were pregnant or lactating at the time of
152 enrollment, 2) patients with mental retardation, addictive disorders, and 3) patients
153 with specific systemic diseases, metabolic disorders, or medical conditions such as
154 diabetes mellitus, dyslipidemia, cardiovascular diseases, and hypertension.

155 *2.3 Randomization*

156 Participants were randomly assigned 1:1 to olanzapine+ or olanzapine through a
157 computer-generated random number. A research nurse conducted the randomization.
158 Treating clinicians were not blinded to trial groups, but independent assessors who
159 were blinded to the information on the treatment group evaluated all primary and
160 most of the secondary outcomes.

161 *2.4 Intervention*

162 The participants were randomly assigned by investigators to a 12-week treatment of
163 olanzapine+, with olanzapine (15-20mg/day at 8:00 p.m.) plus probiotics (Bifico,
164 triple live bacteria oral capsule, 1680 mg/day, 840mg bid), or olanzapine
165 (15-20mg/day at 8:00 p.m.). Bifico (Shanghai Xinyi Pharmaceutical Inc., Shanghai,
166 China), supplied by the manufacturer, is one kind of commonly used probiotics
167 supplement in China and contains live bacteria of *Bifidobacterium*, *Lactobacillus*
168 and *Enterococcus* at least 5.0×10^7 CFU/g. The participants' adherences to probiotics
169 and olanzapine treatment for each visit was defined as taking more than 80% of the
170 study drug dosage prescribed for that interval. If a participant was non-adherent,
171 both the patient and caregiver were counseled on the importance of taking the

172 prescribed amount of study medication.

173 *2.5 Outcome Measures*

174 Primary outcomes were the change in fasting serum insulin, insulin resistance, body
175 mass index (BMI), and weight gain. BMI is calculated as weight in kilograms
176 divided by height in meter squared, and insulin resistance was calculated based on a
177 formula of homeostatic model assessment for insulin resistance (HOMA-IR), by
178 fasting insulin [mIU/L]x fasting glucose [mmol/L]/22.5.

179 Secondary outcomes were 1) the increase in the levels of lipids, including
180 high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol
181 (LDL), total cholesterol, and triglyceride, 2) Psychopathologic symptoms measured
182 by positive and negative symptom scales (PANSS), and 3) appetite increase. We
183 used a self-reported scale to evaluate appetite. The scale included four items: how
184 hungry you are, how full you are, how strong desire to eat, and how much food you
185 think you can eat. They were measured at a scale of 0-10. A composite score was
186 calculated to measure the overall appetite increase. Compared with baseline, the
187 composite score increased ≥ 1 was defined as appetite increase, decreased ≥ 1 was
188 defined as appetite decrease, and an increase or decrease less than 1 was defined as
189 no change in appetite.

190 *2.6 Sample size*

191 The sample size was calculated for the primary outcome of HOMA-IR based on the
192 Hotelling-Lawley F test with a linear exponent autoregressive correlation structure
193 (Xu et al., 2020), a base correlation of 0.8, and decay of 0.3 over the time. The total

194 sample size required for a power of 80%, a level of 0.05 with a standard deviation of
195 0.6 and 0.8 were 44 and 74, respectively; and our actual sample of 76 patients met
196 the calculation.

197 *2.7 Data collection*

198 All patients who received the treatment were scheduled to having a clinical
199 evaluation through the scheduled follow-up at week 4, 8, and 12. The baseline
200 assessments included demographics, a comprehensive medical history, physical
201 examination, anthropometric measurements (weight and height), and PANSS score.
202 The laboratory tests at baseline included fasting glucose, lipids and insulin, liver and
203 renal function, blood counts, and electrocardiogram. At each follow-up visit, all
204 baseline clinical evaluations, including physical examination, anthropometric
205 measurements, and laboratory tests, were repeated. The Treatment Emergent
206 Symptom Scale (TESS) (Guy) was used to record adverse events throughout the
207 clinical trial. PANSS were also evaluated at week 12, the end of the trial.

208 We assessed the appetite half an hour before lunch every day within the first two
209 weeks of the treatments and at each follow-up visit.

210 *2.8 Statistical Analysis*

211 Data were examined and processed before the analysis. Summary statistics including
212 mean, median, and standard deviation were calculated for all variables at baseline
213 and each follow-up. Through a comparison of mean and median, one can have a
214 quick assessment of any severe violation of the fair assumption for the statistical
215 methods used for analysis (Zhang and Hughes, 2019). General linear random-effect
216 model (José A. Apud et al., 2012; Wu et al., 2016; Xu et al., 2020) was employed to

217 estimate the fixed-effect of treatments on primary and secondary outcomes over time
218 after adjustment for the baseline characteristics of age, sex, duration of illness, which
219 provide a better analysis in presence of missing or dropouts than the last observation
220 carried forward. The covariance matrix chooses first-order autoregressive [AR (1)]
221 over the time of treatment. Post-hoc least square estimates of mean and standard
222 errors were obtained for graphic presentation; correction for multiple testing was
223 performed using Dunnett's test to compare the outcomes at each follow-up visit with
224 the baselines. The analysis was performed using SPSS and SAS/STAT 13.2; a
225 two-sided level of 0.05 was considered as statistically significant.

226 Ancillary analyses were also performed on the four primary outcomes while
227 adjusting for the status of appetite increase, which was coded as a binary outcome.
228 The main effect of appetite increase, plus the interaction between appetite increase
229 and treatment time was included in the regression model to assess the treatment
230 effect over time. The report of the study followed the CONSORT 2010 Statement
231 updated guidelines for reporting parallel group randomized trials and related
232 recommendations for reporting of clinical trials as well as calls for transparency in
233 the report for clinical and preclinical research (Landis et al., 2012; Zhang and
234 Hughes, 2019).

235 **3. Results**

236 Participants were recruited from November 30, 2017, to February 01, 2019. Of 126
237 patients screened for eligibility (**Figure 1**), 17 patients did not meet the inclusion or
238 met exclusion criteria, 19 patients declined to participate; 90 patients were randomly
239 and equally assigned to the group of olanzapine+ or olanzapine monotherapy. During
240 the trial period, 14 patients did not receive intervention with medication as

241 randomized or withdrew the consent; so, 76 patients were evaluated with follow-up
242 to collect the outcome measurements, which included 39 patients in the olanzapine+
243 and 37 in the olanzapine, who were followed at least one time. Finally, 88.2% of
244 patients completed the 12-week treatment. We examined the nine individuals who
245 did not complete the follow-up at week 8 or 12, found no significant difference in
246 baseline characteristics of patients from those patients who completed all follow-ups
247 (**Table S1**).

248 **Table 1** presents the demographics and characteristics of the patients by treatment
249 group. There was no significant difference in all the variables between groups,
250 which were expected due to the randomized assignments. About 65-72% of the
251 patients were females, and 35-36% were cigarette smokers. The mean age was 24
252 years, and the duration of illness was about 11 months; the total PANSS score was
253 about 80. The baseline characteristics and outcome measures were not different
254 ($p>0.05$) between two treatments except for a slight difference in LDL ($p=0.0017$)
255 and total cholesterol ($p=0.037$), which were higher in the olanzapine+ than in the
256 olanzapine monotherapy. The higher level of LDL and total cholesterol at baseline
257 assured at least no over-estimation of the interventional effect of probiotic
258 supplements on the secondary outcomes when olanzapine+ are assumed to reduces
259 the metabolic disturbance of lipid profiles. The summary statistics of the key
260 outcomes at baseline and follow-up time points by treatment group were presented
261 in the supplementary (**Table S2**)

262 *3.1 Primary outcomes*

263 **Figure 2** provides an intuitive display of the treatment effects over time. The
264 addition of probiotic supplements concurrently with olanzapine medication

265 significantly slowed the increase in fasting insulin ($p<0.0001$) and HOMA-IR
266 ($p=0.0005$), but only had a slight effect on reducing the increase in BMI ($p=0.077$)
267 and weight gain ($p=0.051$).

268 **Table 2** provides the detailed estimates of treatment effect. Specifically, patients
269 received treatment of olanzapine+ had an increase in the levels of fasting insulin by
270 2.45 uIU/mL, from 7.81 at baselines to 10.26 at week 12 ($p<0.0001$), which was much
271 lower than an increase by 6.03 uIU/mL ($p<0.0001$), from 7.69 at baselines to 13.72
272 at week 12 in the olanzapine monotherapy, and there was a significant difference in
273 the level of fasting insulin at the end of the trial between two groups (difference,
274 -3.46, 95% CI [-5.0,-1.91]; $p<0.0001$). Similarly, the HOMA-IR increased by 0.63
275 ($p<0.0001$), from 1.54 at the baseline to 2.17 at week 12 in the olanzapine+ group,
276 which was lower than the increase by 1.27 ($p<0.0001$), from 1.51 at the baselines to
277 2.78 at week 12 in the olanzapine monotherapy; also, there was a significant
278 difference in the HOMA-IR at the end of the trial between two groups (difference,
279 -0.61, 95% CI [-0.94,-0.28]; $p=0.0004$). Both BMI and body weight significantly
280 increased at week 4 compared with baseline and continued to increase throughout
281 the study in both the olanzapine+ and olanzapine group, but overall, these increases
282 were not significantly different between the two treatment groups ($p>0.05$).

283 *3.2 Secondary outcomes*

284 *Appetite increase*

285 Olanzapine plus probiotic supplements slightly reduced appetite increase. In the
286 olanzapine+ group, 38.5% (15/39) of patients had appetite increase, which was
287 lower than 56.8% (21/37) in the olanzapine group (log-rank test, $p=0.0666$;
288 likelihood ratio test, $p=0.0255$) (**Figure S1**). The difference in the appetite increase

289 became no significant ($p=0.1211$) between two treatments after adjustment for sex,
290 age, duration of illness, and dosage of olanzapine taken in the Cox regression
291 analysis. However, on average, patients treated with olanzapine+ were about 40%
292 less likely (Hazard Ratio, HR=0.589) to have an increase in appetite than those who
293 received olanzapine monotherapy (**Table S3**).

294 Psychopathological symptoms

295 The psychopathological symptoms improved in both groups after treatment for 12
296 weeks but the improvement was not significantly different between groups. The
297 PANSS total score was reduced by 24.5 ($p<0.0001$) from 80.18 at the baseline to
298 55.67, after olanzapine+ for 12 weeks and by 22.7 ($p<0.0001$), from 79.5 at the
299 baseline to 56.8, after olanzapine treatment. However, the improvement of PANSS
300 total score was not significantly different between two groups ($p=0.48$). We also
301 observed a similar pattern in positive, negative, and the general psychopathology
302 (**Table S4**).

303 Lipid profiles

304 The lipid profiles that comprised triglyceride, total cholesterol, HDL, and LDL
305 increased very significantly ($p<0.0001$) in both the olanzapine+ and the olanzapine
306 group, but no significant difference in triglyceride ($p=0.21$), HDL ($p=0.60$) and LDL
307 ($p=0.55$), except total cholesterol ($p=0.028$) between two treatment groups (**Table**
308 **S5**).

309 *3.3 Appetite modulated antipsychotics-induced metabolic change*

310 While the addition of probiotic supplements slightly reduced the likelihood and
311 timing of the change in appetite, which had a significant effect on the metabolic

312 disturbance in both groups. Patients with appetite increase had a significant
313 ($p<0.0001$) elevation of all primary outcomes of fasting insulin, HOMA-IR, BMI,
314 and weight than those patients without appetite increase (**Table 3**). The metabolic
315 disturbance increased gradually with the duration of treatment and became
316 significant at week 12 in BMI ($p=0.028$), fasting insulin ($p<0.0001$), and HOMA-IR
317 ($p<0.0001$). However, we noted that the significant differences between two groups
318 in weight gain were primarily driven by the baseline measurements, in which the
319 weight was significantly different ($p=0.0065$) at baseline but no difference after
320 treatment at week 12 ($p=0.28$). Of note, appetite also modulated the
321 antipsychotic-induced changes in the secondary outcomes such as triglyceride
322 ($p=0.019$), total cholesterol ($p=0.0002$), and LDL ($p<0.0001$), but not in HDL
323 ($p=0.054$).

324 *3.4 Ancillary analysis*

325 We further investigated if the effect of probiotic supplements on the metabolic
326 disturbance was through the less increase in appetite (**Table S6**). After adjustment
327 for the status of appetite increase, probiotic supplements still significantly reduced
328 the increase in fasting insulin ($p<0.0001$) and HOMA-IR ($p=0.0012$); the effect also
329 started at week 8 after treatment, suggesting that the impact of probiotic supplements
330 on the increase in fasting insulin and HOMA-IR were mostly independent of appetite
331 increase. However, two treatments had no significant impact on the change in BMI
332 ($p=0.143$) and body weight ($p=0.11$) during the trial after adjustment for appetite
333 increase.

334 *3.5 Adverse events*

335 Adverse events considered grade 3 or higher that were reported at least 5% of the

336 evaluable patients (**Table 4**). The most common adverse events in both groups were
337 hypoactivity (26-30%), somnolence (26-27%), and abnormal in liver function test
338 (15-16%), but they were not significantly different between the two treatment groups.
339 The only adverse event reported as possibly related to the probiotic supplements was
340 diarrhea, which was 10% in the olanzapine+ but only 3% in the olanzapine group. In
341 contrast, constipation was 3% in olanzapine+, but 14% in the olanzapine
342 monotherapy. None of these was suitable for pursuing a formal statistical test due to
343 small sample size.

344 **4. Discussion**

345 The main findings of this trial were that probiotic supplements with olanzapine
346 attenuated antipsychotics-induced elevation of fasting serum insulin and insulin
347 resistance as measured by HOMA-IR while retaining the treatment effect on
348 psychopathological symptoms. However, we did not find a significant benefit on
349 BMI and weight gain, nor the secondary outcomes of appetite increase as well as
350 lipid profiles. Our study provided the first evidence for probiotic supplements in
351 preventing antipsychotics-induced insulin resistance in patients with drug-naive
352 first-episode schizophrenia while concurrently using antipsychotics.

353 Our findings that probiotic supplements reduced the olanzapine-induced increase in
354 fasting insulin and insulin resistance were consistent with previous multiple studies
355 in individuals with diabetic conditions. 1) One randomized, double-blind,
356 placebo-controlled trial in Thailand finds that supplementation of probiotics
357 containing *Bifidobacterium* (*B.*) and *Lactobacillus* (*L.*) daily for four consecutive
358 weeks improves the plasma fasting insulin and HOMA-IR in women diagnosed with
359 gestational diabetes mellitus (GDM) between 24–28 weeks (Kijmanawat et al.,

360 2019), compared to the placebo group; 2) In another randomized clinical trial (RCT)
361 in Ukraine, supplementation of multi-probiotics, including concentrated biomass of
362 14 probiotic bacteria genera *Bifidobacterium*, *Lactobacillus*, *Lactococcus*,
363 *Propionibacterium* for eight weeks, was associated with the reduction of HOMA-IR
364 in individuals with type 2 diabetes (Kobyliak et al., 2018). Both trials used probiotics
365 that contain *Bifidobacterium* and *Lactobacillus*, two common bacteria for probiotics,
366 as that used in our study; 3) A meta-analysis of six RCTs involved 830 patients also
367 confirmed that supplementation of probiotics significantly reduced the serum fasting
368 insulin and HOMA-IR in women with GDM (Pan et al., 2019). In addition, in a
369 double blind, randomized, placebo-controlled parallel-group clinical trial for 24
370 weeks, glycemic conditions can be improved significantly by probiotics, particularly
371 synbiotic (prebiotic plus probiotic) supplements in pre-diabetic individuals (Kassaian
372 et al., 2018). Insulin resistance plays a crucial role in the olanzapine-induced
373 metabolic disturbance, including lipid profiles and weight gain (Wu et al., 2016; Wu
374 et al., 2008), which at least partly depends on appetite increase (Davoodi et al., 2009).
375 However, we found that the benefit of probiotic supplements on preventing the
376 olanzapine-induced insulin resistance was still significant regardless of appetite
377 increase.

378 Our study did not find a significant effect of probiotic supplements on the lipid
379 profiles, although reports have shown that probiotics have a significant effect on
380 lipid metabolism. In the most recent meta-analysis of ten RCTs with 1,139
381 participants, probiotics supplements were shown to have improved effect on glucose,
382 HOMA-IR, and lipid metabolism in pregnant women (Han et al., 2019). A
383 meta-analysis of 13 RCTs with 485 patients with high, borderline high, or healthy
384 cholesterol also shows that a diet rich in probiotics decreases the total cholesterol

385 and LDL cholesterol concentration in plasma (Guo et al., 2011). In addition, an RCT
386 study of vitamin D plus probiotic supplements (8×10^9 CFU), containing *B.bifidum*,
387 *L.acidophilus*, *L.reuteri*, and *L.fermentum* (each 2×10^9) for 12 weeks in patients
388 with chronic schizophrenia who had used but not concurrently with antipsychotics,
389 showed a significant effect on the improvement of metabolic profiles including
390 fasting glucose, fasting insulin and HOMA-IR, triglycerides and total cholesterol
391 levels (Ghaderi et al., 2019). The limited effect of probiotic supplements on lipid
392 profiles could be due to the short duration of treatment in this trial because our
393 previous trials of metformin on antipsychotic-induced dyslipidemia in schizophrenia
394 indicate that the treatment effect on lipids requires a prolonged duration of treatment
395 (24 weeks) than on insulin or insulin resistance (12 weeks) (Wu et al., 2016).

396 Increasing evidence shows that there is a strong metabolic risk intrinsic to
397 schizophrenia even in the absence of antipsychotic drug treatment (Freyberg et al.,
398 2017). As in this study with drug-naive patients, we noted elevated levels of lipids in
399 one of the groups. This would make a study of definitive mechanisms more
400 challenging for antipsychotic-induced metabolic disturbance. There have been
401 studies indicating that genetic variants at *TCF7L2* and *PSMD9* were independently
402 associated with schizophrenia and type 2 diabetes (Freyberg et al., 2017). In addition,
403 the central nervous system (e.g. hypothalamus) where the neurotransmitter and
404 neuropeptide system such as dopamine, serotonin, and histamine may play a role in
405 the intrinsic metabolic risk. This is because that almost all antipsychotics act on
406 dopamine receptors (D2 and D3) and/or serotonin receptors, and polymorphism in
407 *DRD2*, *DRD3*, *5HT2a*, and *5HT2c* have been associated with both
408 antipsychotic-induced metabolic dysfunction and schizophrenia (Freyberg et al.,
409 2017). In fact, some polymorphisms in *TCF7L2* and *DRD2* have been found to be

410 shared by schizophrenia, bipolar, and major depressive disorders (Xia et al., 2019).
411 The effect of probiotic supplements on the levels of fast insulin and insulin
412 resistance may support that the gut-brain axis plays a role in modulating
413 antipsychotic-induced metabolic dysfunction and might have implications for
414 reducing the risk of schizophrenia at least for a partial population of the patients with
415 schizophrenia.

416 To our knowledge, this was the first study to assess probiotic supplements on
417 preventing olanzapine-induced metabolic disturbance and weight gain in drug naïve
418 first-episode patients with schizophrenia. Supplementation of probiotics was in favor
419 of preventing olanzapine-induced elevation of fasting serum insulin and insulin
420 resistance, and was shown to be well tolerated and safe in the participants.

421 *4.1 Limitation*

422 This study had some limitations. First, we did not use a placebo in this trial, although
423 the treatment information was blinded to the clinical evaluators. Second, this was a
424 12-week trial, and about 20% of patients were lost to follow-up due to the inability
425 to take the medication as a randomized assignment. In such a limited duration of
426 treatment, we did not know whether the improved insulin sensitivity could sustain
427 after patients stopped taking probiotic supplements. Third, this was a single-center
428 clinical trial, which had the advantage of homogenous samples but may not allow us
429 to address the variability across regions. Therefore, it may limit the generalizability
430 of the study results to the study population in a south-central province of China. In
431 addition, some related measurements such as adiposity and leptin levels were not
432 measured; we did not examine the microbiome that would strengthen the study and
433 help reveal the underlying mechanism of treatment response. These may require

434 additional effort such as funding support and development of study protocols.

435 *4.2 Generalizability*

436 Despite some limitations, our study provided the first evidence that probiotic
437 supplements can be used for preventing antipsychotic-induced metabolic disturbance
438 in particular elevation of fasting insulin and insulin resistance. Given that probiotic
439 supplements were generally safe for use, as shown in this trial, the study results may
440 have implications for clinical practice, the supplementations of probiotics can be
441 recommended for concurrent use with antipsychotic treatment in patients with
442 schizophrenia in the study population in the area where the study was conducted. In
443 addition, further research is needed to assess the effect of the probiotic supplements
444 on antipsychotic-induced weight gain and metabolic disturbance in a longer-term
445 and potentially synergistic effect on antipsychotic response.

446 **Role of the funding source**

447 Funding. The research was supported by the Key R&D Program Projects, National
448 Science Foundation of China (Grant No.2016YFC1306900), and the National Natural
449 Science Foundation of China (Grant No.81622018), Beijing Haiju Scholarship
450 (BHTO201511097).

451 Declarations of Interest: None.

452 Contributors: RW, JZ applied the funding for the trial. RW, JD conceived the trial. DK,
453 YY, CL, JX, YL, JH, XP, WW, and XW were involved in patient recruitment. RW,
454 FZ, and JZ were involved in study quality control. Statistical analyses were performed
455 by RW and FZ. DK and FZ wrote the manuscript. All authors provided critical
456 comments. All authors approved the final version of the manuscript.

457 Acknowledgement: We would like to thank all the participants and researchers who

458 have been involved in the research.

459

460 REFERENCES

- 461 Bäckhed, F., Ding, H., Wang, T., Hooper, L.V., Koh, G.Y., Nagy, A., Semenkovich, C.F., Gordon, J.I., 2004.
462 The gut microbiota as an environmental factor that regulates fat storage. *Proceedings of the National*
463 *Academy of Sciences of the United States of America* 101(44), 15718-15723.
- 464 Bäckhed, F., Manchester, J.K., Semenkovich, C.F., Gordon, J.I., 2007. Mechanisms underlying the
465 resistance to diet-induced obesity in germ-free mice. *Proceedings of the National Academy of*
466 *Sciences of the United States of America* 104(3), 979-984.
- 467 Bahr, S.M., Tyler, B.C., Wooldridge, N., Butcher, B.D., Burns, T.L., Teesch, L.M., Oltman, C.L.,
468 Azcarate-Peril, M.A., Kirby, J.R., Calarge, C.A., 2015. Use of the second-generation antipsychotic,
469 risperidone, and secondary weight gain are associated with an altered gut microbiota in children.
470 *Transl Psychiatry* 5, e652.
- 471 Bahra, S.M., Weidemann, B.J., Castro, A.N., Walsh, J.W., deLeon, O., Burnett, C.M., Pearson, N.A.,
472 Murry, D.J., Grobe, J.L., Kirby, J.R., 2015. Risperidone-induced weight gain is mediated through shifts
473 in the gut microbiome and suppression of energy expenditure. *EBioMedicine* 2(11), 1725-1734.
- 474 Bretler, T., Weisberg, H., Koren, O., Neuman, H., 2019. The effects of antipsychotic medications on
475 microbiome and weight gain in children and adolescents. *BMC medicine* 17(1), 112.
- 476 Cani, P.D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A.M., Delzenne, N.M., Burcelin, R., 2008.
477 Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat
478 diet-induced obesity and diabetes in mice. *Diabetes* 57(6), 1470-1481.
- 479 Chen, J., Huang, X.F., Shao, R., Chen, C., Deng, C., 2017. Molecular Mechanisms of Antipsychotic
480 Drug-Induced Diabetes. *Frontiers in neuroscience* 11, 643.
- 481 Correll, C.U., Manu, P., Olshanskiy, V., Napolitano, B., Kane, J.M., Malhotra, A.K., 2009.
482 Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children
483 and adolescents. *Jama* 302(16), 1765-1773.
- 484 Davey, K.J., Cotter, P.D., O'Sullivan, O., Crispie, F., Dinan, T.G., Cryan, J.F., O'Mahony, S.M., 2013.
485 Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by
486 antibiotic administration in the rat. *Translational psychiatry* 3, e309.
- 487 Davey, K.J., O'Mahony, S.M., Schellekens, H., O'Sullivan, O., Bienenstock, J., Cotter, P.D., Dinan, T.G.,
488 Cryan, J.F., 2012. Gender-dependent consequences of chronic olanzapine in the rat: effects on body
489 weight, inflammatory, metabolic and microbiota parameters. *Psychopharmacology* 221(1), 155-169.
- 490 Davoodi, N., Kalinichev, M., Korneev, S.A., Clifton, P.G., 2009. Hyperphagia and increased meal size
491 are responsible for weight gain in rats treated sub-chronically with olanzapine. *Psychopharmacology*
492 203(4), 693-702.
- 493 De Hert, M., Detraux, J., van Winkel, R., Yu, W., Correll, C.U., 2011. Metabolic and cardiovascular
494 adverse effects associated with antipsychotic drugs. *Nature reviews. Endocrinology* 8(2), 114-126.
- 495 Foley, D.L., Morley, K.I., 2011. Systematic review of early cardiometabolic outcomes of the first
496 treated episode of psychosis. *Arch Gen Psychiatry* 68(6), 609-616.
- 497 Freyberg, Z., Aslanoglou, D., Shah, R., Ballon, J.S., 2017. Intrinsic and Antipsychotic Drug-Induced
498 Metabolic Dysfunction in Schizophrenia. *Frontiers in neuroscience* 11(432).
- 499 Ghaderi, A., Banafshe, H.R., Mirhosseini, N., Moradi, M., Karimi, M.A., Mehrzad, F., Bahmani, F.,
500 Asemi, Z., 2019. Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients.
501 *BMC psychiatry* 19(1), 77.
- 502 Guo, Z., Liu, X.M., Zhang, Q.X., Shen, Z., Tian, F.W., Zhang, H., Sun, Z.H., Zhang, H.P., Chen, W., 2011.
503 Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised

504 controlled trials. *Nutrition, metabolism, and cardiovascular diseases* : NMCD 21(11), 844-850.

505 Guy, W., *ECDEU Assessment Manual for Psychopharmacology, Revised*. US Department of Health,
506 Education, and Welfare: Public Health Service, Alcohol, Drug Abuse and Mental Health
507 Administration., Rockville, MD.

508 Hahn, M.K., Wolever, T.M., Arenovich, T., Teo, C., Giacca, A., Powell, V., Clarke, L., Fletcher, P., Cohn, T.,
509 McIntyre, R.S., Gomes, S., Chintoh, A., Remington, G.J., 2013. Acute effects of single-dose olanzapine
510 on metabolic, endocrine, and inflammatory markers in healthy controls. *Journal of clinical*
511 *psychopharmacology* 33(6), 740-746.

512 Han, M.M., Sun, J.F., Su, X.H., Peng, Y.F., Goyal, H., Wu, C.H., Zhu, X.Y., Li, L., 2019. Probiotics improve
513 glucose and lipid metabolism in pregnant women: a meta-analysis. *Annals of translational medicine*
514 7(5), 99.

515 José A. Apud, M.D., Ph.D. , Fengyu Zhang, Ph.D. , Heather Decot, B.S. , Kristin L. Bigos, Ph.D. , and,
516 Daniel R. Weinberger, M.D., 2012. Genetic Variation in KCNH2 Associated With Expression in the
517 Brain of a Unique hERG Isoform Modulates Treatment Response in Patients With Schizophrenia.
518 *American Journal of Psychiatry* 169(7), 725-734.

519 Kang, D.-Y., Li, S.-J., Liu, C.-C., Wu, R.-R., 2019. Gut microbiota and antipsychotic induced metabolic
520 alteration. *Glob Clin Transl Res* 1(4), 131-143.

521 Kassaian, N., Feizi, A., Aminorroaya, A., Jafari, P., Ebrahimi, M.T., Amini, M., 2018. The effects of
522 probiotics and synbiotic supplementation on glucose and insulin metabolism in adults with
523 prediabetes: a double-blind randomized clinical trial. *Acta diabetologica* 55(10), 1019-1028.

524 Khanna, S., Tosh, P.K., 2014. A clinician's primer on the role of the microbiome in human health and
525 disease. *Mayo Clinic proceedings* 89(1), 107-114.

526 Kijmanawat, A., Panburana, P., Reutrakul, S., Tangshewinsirikul, C., 2019. Effects of probiotic
527 supplements on insulin resistance in gestational diabetes mellitus: A double-blind randomized
528 controlled trial. *Journal of diabetes investigation* 10(1), 163-170.

529 Kirk, S.L., Glazebrook, J., Grayson, B., Neill, J.C., Reynolds, G.P., 2009. Olanzapine-induced weight gain
530 in the rat: role of 5-HT2C and histamine H1 receptors. *Psychopharmacology* 207(1), 119-125.

531 Kobylak, N., Falalyeyeva, T., Mykhalchyshyn, G., Kyriienko, D., Komissarenko, I., 2018. Effect of alive
532 probiotic on insulin resistance in type 2 diabetes patients: Randomized clinical trial. *Diabetes &*
533 *metabolic syndrome* 12(5), 617-624.

534 Landis, S.C., Amara, S.G., Asadullah, K., Austin, C.P., Blumenstein, R., Bradley, E.W., Crystal, R.G.,
535 Darnell, R.B., Ferrante, R.J., Fillit, H., Finkelstein, R., Fisher, M., Gendelman, H.E., Golub, R.M.,
536 Goudreau, J.L., Gross, R.A., Gubitza, A.K., Hesterlee, S.E., Howells, D.W., Huguenard, J., Kelner, K.,
537 Koroshetz, W., Krainc, D., Lazic, S.E., Levine, M.S., Macleod, M.R., McCall, J.M., Moxley, R.T., 3rd,
538 Narasimhan, K., Noble, L.J., Perrin, S., Porter, J.D., Steward, O., Unger, E., Utz, U., Silberberg, S.D.,
539 2012. A call for transparent reporting to optimize the predictive value of preclinical research. *Nature*
540 490(7419), 187-191.

541 Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S.,
542 Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J., Hsiao, J.K., *Clinical Antipsychotic Trials of*
543 *Intervention Effectiveness*, I., 2005. Effectiveness of antipsychotic drugs in patients with chronic
544 schizophrenia. *The New England journal of medicine* 353(12), 1209-1223.

545 Maayan, L., Correll, C.U., 2011. Weight gain and metabolic risks associated with antipsychotic
546 medications in children and adolescents. *Journal of child and adolescent psychopharmacology* 21(6),
547 517-535.

548 Murphy, E.F., Cotter, P.D., Hogan, A., O'Sullivan, O., Joyce, A., Fouhy, F., Clarke, S.F., Marques, T.M.,
549 O'Toole, P.W., Stanton, C., Quigley, E.M., Daly, C., Ross, P.R., O'Doherty, R.M., Shanahan, F., 2013.
550 Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in
551 diet-induced obesity. *Gut* 62(2), 220-226.

552 Nasrallah, H.A., 2008. Atypical antipsychotic-induced metabolic side effects: insights from
553 receptor-binding profiles. *Mol Psychiatry* 13(1), 27-35.

554 Newcomer, J.W., 2005. Second-generation (atypical) antipsychotics and metabolic effects: a
555 comprehensive literature review. *CNS drugs* 19 Suppl 1, 1-93.

556 Newcomer, J.W., 2007. Metabolic considerations in the use of antipsychotic medications: a review of
557 recent evidence. *The Journal of clinical psychiatry* 68 Suppl 1, 20-27.

558 Pan, J., Pan, Q., Chen, Y., Zhang, H., Zheng, X., 2019. Efficacy of probiotic supplement for gestational
559 diabetes mellitus: a systematic review and meta-analysis. *The journal of maternal-fetal & neonatal*
560 *medicine : the official journal of the European Association of Perinatal Medicine, the Federation of*
561 *Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet* 32(2), 317-323.

562 van Winkel, R., De Hert, M., Wampers, M., Van Eyck, D., Hanssens, L., Scheen, A., Peuskens, J., 2008.
563 Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation
564 of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective
565 disorder. *The Journal of clinical psychiatry* 69(3), 472-479.

566 Wu, R.R., Zhang, F.Y., Gao, K.M., Ou, J.J., Shao, P., Jin, H., Guo, W.B., Chan, P.K., Zhao, J.P., 2016.
567 Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized,
568 placebo-controlled trials. *Mol Psychiatry* 21(11), 1537-1544.

569 Wu, R.R., Zhao, J.P., Jin, H., Shao, P., Fang, M.S., Guo, X.F., He, Y.Q., Liu, Y.J., Chen, J.D., Li, L.H., 2008.
570 Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a
571 randomized controlled trial. *Jama* 299(2), 185-193.

572 Xia, L., Xia, K., Weinberger, D.R., Zhang, F., 2019. Common genetic variants shared among five major
573 psychiatric disorders: a large-scale genome-wide combined analysis. *Glob Clin Transl Res.* 1(1), 21-30.

574 Xu, Z., Xie, C., Xia, L., Yuan, Y., Zhu, H., Huang, X., Li, C., Tao, Y., Qu, X., Zhang, F., Zhang, Z., 2020.
575 Targeted exome sequencing identifies five novel loci at genome-wide significance for modulating
576 antidepressant response in patients with major depressive disorder. *Translational psychiatry* 10(1),
577 30.

578 Zhang, F., Hughes, C., 2019. Reporting standards for clinical and translational research. *Glob Clin*
579 *Transl Res* 1(2), 69-73.

580

581

Table 1. Baseline Characteristics of the Patients by Treatment Group

	Olanzapine plus probiotics (N=39)							Olanzapine monotherapy (N=37)							Normal range
	Mean	Med	SD	Min	5%	95%	Max	Mean	Med	SD	Min	5%	95%	Max	
Female	72%							65%							
Smoking	36%							35%							
Age, year	24.82	22.00	5.64	18.00	18.00	36.00	38.00	23.43	22.00	4.89	18.00	18.00	35.00	36.00	
Duration of illness, month	11.49	11.00	3.51	6.00	6.00	18.00	18.00	11.08	10.00	3.64	5.00	6.00	18.00	18.00	
Dose of olanzapine, mg	19.36	20.00	1.59	15.00	15.00	20.00	20.00	18.85	20.00	1.92	15.00	15.00	20.00	20.00	
Weight, kg	55.63	53.00	7.54	47.00	48.00	72.00	74.70	56.75	56.00	8.35	45.00	45.00	70.00	72.00	
Body mass index, kg/m ²	21.26	20.70	2.59	18.22	18.29	29.26	29.92	21.25	21.33	1.69	18.03	18.73	23.94	23.94	18.5-23.9 kg/m ²
Fasting glucose, mmol/L	4.41	4.34	0.39	3.39	3.96	5.30	5.30	4.40	4.30	0.37	3.90	3.90	5.30	5.30	3.9-6.1 mmol/L
Fasting insulin, uIU/mL	8.07	7.60	2.88	3.50	3.60	14.50	15.60	7.85	7.50	1.72	4.90	4.90	11.20	12.30	6.4-15.0 uIU/mL
HOMA-Insulin Resistance	1.59	1.41	0.59	0.70	0.81	2.84	2.96	1.54	1.53	0.38	0.85	0.91	2.34	2.35	<2.67
Triglyceride, mmol/L	0.86	0.76	0.41	0.28	0.32	1.78	1.84	0.72	0.68	0.26	0.32	0.38	1.22	1.23	<1.71 mmol/L
Total cholesterol, mmol/L ^a	3.75	3.60	0.58	2.80	2.89	4.70	4.80	3.70	3.57	0.48	3.10	3.11	4.56	4.57	2.9-5.2 mmol/L
HDL, mmol/L	1.21	1.17	0.18	0.92	0.93	1.60	1.67	1.23	1.20	0.14	1.04	1.05	1.56	1.60	>1.04 mmol/L
LDL, mmol/L ^a	2.39	2.40	0.44	1.60	1.65	3.10	3.23	2.10	2.04	0.36	1.45	1.65	2.89	3.10	<3.12 mmol/L
Score of appetite scale	5.7	5.8	0.60	4.5	5	7	7.5	6.0	6.0	0.5	5	5	6.8	7	
Total score of PANSS	79.77	78.00	5.37	70.00	70.00	88.00	89.00	79.65	80.00	7.37	68.00	70.00	93.00	93.00	

Abbreviations: Med, median; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

^a, $p < 0.05$, compared between the two treatment groups.

Table 2. Estimates of Treatment Effect on Primary Outcomes by Group

	Olanzapine+				Olanzapine				Beta	Group difference		P	P ^a
	N	LS Mean	SE	P _{adj}	N	LS mean	SE	P _{adj}		SE	95%CI		
Fasting Insulin, uIU/mL													
Baseline	35	7.81	0.564	ref	36	7.69	0.553	ref	0.119	0.772	-1.394, 1.632	0.8775	<.0001
4 Weeks	35	7.61	0.564	0.7352	34	8.22	0.562	0.6315	-0.612	0.78	-2.141, 0.917	0.434	
8 Weeks	33	8.15	0.575	0.5475	34	10.21	0.562	0.0012	-2.061	0.788	-3.605, -0.517	0.0098	
12 Weeks	33	10.26	0.575	<.0001	34	13.72	0.562	<.0001	-3.455	0.788	-4.999, -1.911	<.0001	
HOMA-IR													
Baseline	35	1.54	0.121	ref	36	1.51	0.118	ref	0.037	0.165	-0.286, 0.360	0.8254	0.0005
4 Weeks	35	1.47	0.121	0.5875	34	1.63	0.12	0.577	-0.151	0.167	-0.478, 0.176	0.3665	
8 Weeks	33	1.6	0.123	0.8024	34	2.06	0.12	0.0007	-0.459	0.169	-0.790, -0.128	0.0073	
12 Weeks	33	2.17	0.123	<.0001	34	2.78	0.12	<.0001	-0.611	0.169	-0.942, -0.280	0.0004	
Body mass index, kg/m ²													
Baseline	39	21.54	0.355	ref	37	21.47	0.359	ref	0.068	0.493	-0.898, 1.034	0.8905	0.077
4 Weeks	39	21.95	0.355	0.0036	37	22.41	0.359	<.0001	-0.465	0.493	-1.431, 0.501	0.3488	
8 Weeks	37	23.32	0.357	<.0001	34	23.92	0.362	<.0001	-0.6	0.497	-1.574, 0.374	0.2308	
12 Weeks	33	24.33	0.361	<.0001	34	24.55	0.362	<.0001	-0.217	0.5	-1.197, 0.763	0.6649	
Weight, kg													
Baseline	39	57.98	0.897		37	58.79	0.907		-0.817	1.247	-3.261, 1.627	0.514	0.051
4 Weeks	39	59.02	0.897	0.0035	37	61.29	0.907	0.0035	-2.273	1.247	-4.717, 0.171	0.0718	
8 Weeks	37	62.55	0.903	<.0001	34	65.16	0.915	<.0001	-2.608	1.257	-5.072, -0.144	0.0409	
12 Weeks	33	65.14	0.913	<.0001	34	66.78	0.915	<.0001	-1.64	1.264	-4.117, 0.837	0.1976	

Abbreviations: Olanzapine+ , olanzapine plus probiotics; HOMA-IR, HOMA insulin resistance.

LS mean, post-hoc least square estimate of mean.

P^a , p value for testing the difference in insulin and body mass index over time between treatments.

P_{adj}, p value for testing the metabolic change versus the baseline within the treatment group.

1 **Table 3. Appetite Modulated Metabolic Disturbance**

	No appetite increase		Appetite increase		Group difference			<i>P</i>	<i>P</i> ^a
	LS mean	SE	LS mean	SE	Beta	SE	95%CI		
Fasting insulin, uIU/mL									
Baseline	7.69	0.52	7.88	0.57	-0.194	0.762	-1.688,1.300	0.7996	<.0001
4 Weeks	7.81	0.52	8.08	0.57	-0.267	0.768	-1.772,1.238	0.7283	
8 Weeks	8.66	0.53	9.81	0.57	-1.146	0.772	-2.659,0.367	0.1402	
12 Weeks	10.27	0.53	13.93	0.57	-3.664	0.772	-5.177,-2.151	<.0001	
HOMA-IR									
Baseline	1.52	0.11	1.54	0.12	-0.012	0.162	-0.330,0.306	0.943	<.0001
4 Weeks	1.55	0.11	1.57	0.12	-0.02	0.163	-0.339, 0.299	0.904	
8 Weeks	1.68	0.11	1.99	0.12	-0.312	0.164	-0.633, 0.009	0.06	
12 Weeks	2.1	0.11	2.91	0.12	-0.815	0.164	-1.136, -0.494	<.0001	
Body mass index, kg/m²									
Baseline	21.93	0.34	21.05	0.36	0.874	0.495	-0.096, 1.844	0.0812	<.0001
4 Weeks	22.21	0.34	22.16	0.36	0.052	0.495	-0.918, 1.022	0.9159	
8 Weeks	23.22	0.34	24.1	0.37	-0.889	0.497	-1.863, 0.085	0.0774	
12 Weeks	23.91	0.34	25.03	0.37	-1.119	0.499	-2.097, -0.141	0.0276	
Body weight, kg									
Baseline	60.05	0.87	56.54	0.93	3.515	1.257	1.051, 5.979	0.0065	<.0001
4 Weeks	60.81	0.87	59.41	0.93	1.394	1.257	-1.070, 3.858	0.2707	
8 Weeks	63.46	0.87	64.34	0.93	-0.874	1.262	-3.348, 1.600	0.4904	
12 Weeks	65.31	0.87	66.69	0.94	-1.381	1.267	-3.864, 1.102	0.2788	
Triglycerides, mmol/L									
Baseline	0.84	0.066	0.7	0.071	0.145	0.096	-0.043, 0.333	0.1356	0.019
4 weeks	0.89	0.067	0.84	0.072	0.045	0.097	-0.145, 0.235	0.6447	
8 weeks	1.09	0.067	1.06	0.072	0.033	0.097	-0.157, 0.223	0.732	
12 Weeks	1.23	0.068	1.3	0.073	-0.067	0.098	-0.259, 0.125	0.4983	
Total Cholesterol, mmol/L									
Baseline	3.58	0.091	3.802	0.098	-0.225	0.133	-0.486, 0.036	0.0929	0.0002
4 weeks	3.56	0.092	3.78	0.1	-0.221	0.134	-0.484, 0.042	0.1021	
8 weeks	3.67	0.092	4.07	0.099	-0.407	0.134	-0.670, -0.144	0.003	
12 Weeks	3.72	0.093	4.36	0.1	-0.643	0.136	-0.910, -0.376	<.0001	
HDL, mmol/L									
Baseline	1.19	0.031	1.26	0.033	-0.062	0.045	-0.150, 0.026	0.1654	0.054
4 weeks	1.22	0.031	1.26	0.034	-0.034	0.046	-0.124, 0.056	0.4543	
8 weeks	1.19	0.031	1.2	0.034	-0.006	0.046	-0.096, 0.084	0.8894	
12 Weeks	1.13	0.032	1.07	0.034	0.058	0.046	-0.032, 0.148	0.2085	
LDL, mmol/L									
Baseline	2.32	0.079	2.14	0.085	0.179	0.115	-0.046, 0.404	0.1222	<.0001
4 weeks	2.32	0.08	2.23	0.087	0.096	0.117	-0.133, 0.325	0.4134	
8 weeks	2.49	0.079	2.57	0.086	-0.082	0.116	-0.309, 0.145	0.4803	
12 Weeks	2.51	0.082	2.83	0.088	-0.315	0.119	-0.548, -0.082	0.0089	

2 Abbreviations: HOMA-IR, HOMA insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

3 *P*^a, *p* value for testing the difference in outcomes over time between treatments.

4

5 **Tables 4** Common Adverse Events (>5%) in the two Treatment Groups ^a

Adverse events	Olanzapine plus probiotic (N=39)		Olanzapine monotherapy (N=37)	
	N	%	N	%
Hypoactivity	10	26	11	30
Somnolence	10	26	10	27
Abnormal in liver function test	6	15	6	16
Akathisia	2	5	3	8
Constipation	1	3	5	14
Diarrhea	4	10	1	3
Dizzy	2	5	3	8
Weight gain (7% from baseline)	24	62	27	73

6 ^a, Assessment was based on 76 patients who took at least one dose of olanzapine or olanzapine
7 plus probiotics and were evaluable for adverse event assessment.

8

9 **Figure 1.** Flowchart of Patients in Randomized Trial of Probiotic Supplements for
10 Olanzapine-induced Metabolic Disturbances and Weight Gain

11

12 **Figure 2.** The Estimated Effect of Probiotic supplements on Olanzapine-induced Elevation of
13 Fasting Insulin, Insulin Resistance, Body Mass Index, and Weight

14 Plots were presented with LS mean, and SEM;

15 Body mass index, which is calculated as weight in kilograms divided by height in meters squared;

16 HOMA-IR, Homeostatic Model Assessment of Insulin Resistance, which is calculated as insulin level
17 (mIU/L)×fasting glucose(mmol/L)/22.5;

18 ^a P value for testing the difference in outcomes over time between treatments.



